AIM:BXP

Stock Analysis Report

Executive Summary

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and active pharmaceutical ingredients in Bangladesh.

Snowflake

Fundamentals

Very undervalued with excellent balance sheet.


Similar Companies

Share Price & News

How has Beximco Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.4%

BXP

-1.7%

GB Pharmaceuticals

2.3%

GB Market


1 Year Return

-17.7%

BXP

16.4%

GB Pharmaceuticals

2.5%

GB Market

Return vs Industry: BXP underperformed the UK Pharmaceuticals industry which returned 16.4% over the past year.

Return vs Market: BXP underperformed the UK Market which returned 2.5% over the past year.


Shareholder returns

BXPIndustryMarket
7 Day-1.4%-1.7%2.3%
30 Day-5.6%-0.3%-1.3%
90 Day-17.7%5.7%-1.9%
1 Year-16.2%-17.7%19.9%16.4%7.4%2.5%
3 Year-10.9%-14.7%44.5%30.4%18.8%4.3%
5 Year142.3%118.3%89.7%58.5%36.4%6.8%

Price Volatility Vs. Market

How volatile is Beximco Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Beximco Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: BXP (£0.35) is trading below our estimate of fair value (£0.8)

Significantly Undervalued: BXP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BXP is good value based on its PE Ratio (11.7x) compared to the Pharmaceuticals industry average (20.9x).

PE vs Market: BXP is good value based on its PE Ratio (11.7x) compared to the UK market (16.4x).


Price to Earnings Growth Ratio

Low PEG Ratio: BXP is good value based on its PEG Ratio (0.7x)


Price to Book Ratio

PB vs Industry: BXP is good value based on its PB Ratio (1.2x) compared to the GB Pharmaceuticals industry average (2.3x).


Next Steps

Future Growth

How is Beximco Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

16.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BXP's forecast earnings growth (16.6% per year) is above the savings rate (1.2%).

Earnings vs Market: BXP's earnings (16.6% per year) are forecast to grow faster than the UK market (12.4% per year).

High Growth Earnings: BXP's earnings are forecast to grow, but not significantly.

Revenue vs Market: BXP's revenue (14% per year) is forecast to grow faster than the UK market (4.1% per year).

High Growth Revenue: BXP's revenue (14% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: BXP's Return on Equity is forecast to be low in 3 years time (11.6%).


Next Steps

Past Performance

How has Beximco Pharmaceuticals performed over the past 5 years?

13.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BXP's earnings have grown by 13.4% per year over the past 5 years.

Accelerating Growth: BXP's earnings growth over the past year (13.5%) exceeds its 5-year average (13.4% per year).

Earnings vs Industry: BXP earnings growth over the past year (13.5%) underperformed the Pharmaceuticals industry 24.2%.


Return on Equity

High ROE: BXP's Return on Equity (9.8%) is considered low.


Return on Assets

ROA vs Industry: BXP has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: BXP has significantly improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is Beximco Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: BXP's short term assets (BDT12.8B) exceeds its short term liabilities (BDT10.9B)

Long Term Liabilities: BXP's short term assets (12.8B) exceeds its long term liabilities (6.5B)


Debt to Equity History and Analysis

Debt Level: BXP's debt to equity ratio (36.7%) is considered satisfactory

Reducing Debt: BXP's debt to equity ratio has increased from 22.1% to 36.7% over the past 5 years.

Debt Coverage: BXP's debt is well covered by operating cash flow (27.1%).

Interest Coverage: BXP's interest payments on its debt are well covered by EBIT (5.2x coverage).


Balance Sheet

Inventory Level: BXP has a high level of physical assets or inventory.

Debt Coverage by Assets: BXP's debt is covered by short term assets (assets are 1.204470x debt).


Next Steps

Dividend

What is Beximco Pharmaceuticals's current dividend yield, its reliability and sustainability?

1.52%

Current Dividend Yield


Dividend Yield vs Market

company1.5%marketbottom25%2.0%markettop25%5.4%industryaverage3.0%forecastin3Years3.0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: BXP's dividend (1.52%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (2%).

High Dividend: BXP's dividend (1.52%) is low compared to the top 25% of dividend payers in the UK market (5.44%).

Stable Dividend: BXP's dividend payments have been volatile in the past 10 years.

Growing Dividend: BXP's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (17.8%), BXP's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: BXP's dividends in 3 years are forecast to be well covered by earnings (25.6% payout ratio).


Next Steps

Management

What is the CEO of Beximco Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

10.4yrs

Average management tenure


CEO

Nazmul Hassan 0

10.4yrs

Tenure

0

Mr. Nazmul Hassan, MP has been the Managing Director at Beximco Pharmaceuticals Limited since May 2009. Mr. Hassan served as the Managing Director of Shinepukur Ceramics Limited until November 14, 2013. Pr ...


Management Age and Tenure

10.4yrs

Average Tenure

Experienced Management: BXP's management team is seasoned and experienced (10.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Mohammad Ullah

    Company Secretary & Executive Director

    • Tenure: 0yrs
  • Ali Nawaz

    Chief Finance Officer

    • Tenure: 0yrs
  • Nazmul Hassan

    MD & Director

    • Tenure: 10.4yrs
  • Zakaria Chowdhury

    Director of International Marketing

    • Tenure: 9.8yrs
  • Jamal Choudhury

    Executive Director of Accounts & Finance

    • Tenure: 0yrs
  • Rizvi Kabir

    Director of Marketing

    • Tenure: 0yrs
  • Rabbur Reza

    Chief Operating Officer

    • Tenure: 10.4yrs
  • Prabir Ghose

    Executive Director of Quality Assurance

    • Tenure: 0yrs
  • M. Bhuiyan

    Deputy General Manager of Human Resources

    • Tenure: 0yrs

Board Members

  • Mohammad Ullah

    Company Secretary & Executive Director

    • Tenure: 0yrs
  • Salman Rahman

    Vice Chairman

    • Tenure: 0yrs
  • Abu Bakar Rahman

    Director

    • Tenure: 0yrs
  • Nazmul Hassan

    MD & Director

    • Tenure: 10.4yrs
  • Osman Chowdhury

    Director

    • Tenure: 0yrs
  • Iqbal Ahmed

    Director

    • Tenure: 0yrs
  • Ahmed Sohail Rahman

    Chairman

    • Tenure: 0yrs
  • Shah Hoque (49yo)

    Independent Non-Executive Director

    • Tenure: 4.9yrs

Company Information

Beximco Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Beximco Pharmaceuticals Limited
  • Ticker: BXP
  • Exchange: AIM
  • Founded: 1976
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ৳33.418b
  • Listing Market Cap: ৳307.138m
  • Shares outstanding: 405.56m
  • Website: https://www.beximcopharma.com

Number of Employees


Location

  • Beximco Pharmaceuticals Limited
  • 19 Dhanmondi R/A
  • Road No. 7
  • Dhaka
  • 1205
  • Bangladesh

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BXPHARMADSE (Dhaka Stock Exchange Ltd.)YesOrdinary SharesBDBDTApr 1996
BXPAIM (London Stock Exchange AIM Market)SPON GDR REP ONE ORD SH OF TAKA 10 REG SGBGBPOct 2005
R2WADB (Deutsche Boerse AG)SPON GDR REP ONE ORD SH OF TAKA 10 REG SDEEUROct 2005
R2WABST (Boerse-Stuttgart)SPON GDR REP ONE ORD SH OF TAKA 10 REG SDEEUROct 2005

Biography

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and active pharmaceutical ingredients i ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 20:53
End of Day Share Price2019/10/16 00:00
Earnings2019/03/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.